Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccinia as a vector for gene delivery.

Z Sheng Guo1, David L Bartlett

  • 1University of Pittsburgh, Division of Surgical Oncology, 5150 Center Avenue, Suite 459, Pittsburgh, PA 15232, USA.

Expert Opinion on Biological Therapy
|June 4, 2004
PubMed
Summary

Recombinant vaccinia virus (rVV) shows potential as a gene therapy vector and vaccine. Modified vaccinia virus strains demonstrate enhanced tumor targeting for cancer virotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors.

The journal of liquid biopsy·2026
Same author

Impact of Obesity on Clinical, Physiologic, and Durability Outcomes After Antireflux Surgery in a 2,388-Patient Cohort.

Annals of surgery·2026
Same author

ASO Visual Abstract: A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.

Annals of surgical oncology·2026
Same author

ASO Visual Abstract: Adjuvant Radiotherapy After Pancreaticoduodenectomy for Margin-Negative, Node-Positive Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis.

Annals of surgical oncology·2026
Same author

Non-Secreted Mature Decoy-Resistant IL-18-Armed Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in an Aggressive Murine Ovarian Cancer Model.

Cancers·2026
Same author

A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.

Annals of surgical oncology·2026

Area of Science:

  • Virology
  • Gene Therapy
  • Oncolytic Virotherapy

Background:

  • Gene therapy effectiveness is limited by insufficient gene transduction.
  • Recombinant vaccinia virus (rVV) is a developed gene delivery vector for protein expression and in vivo antigen delivery.
  • rVVs show potential as vaccines due to safety, immunogenicity, and high protein expression.

Purpose of the Study:

  • To review the mechanisms of oncolytic vaccinia virus for cancer virotherapy.
  • To discuss strategies for enhancing vaccinia virus as a gene delivery vector.
  • To explore modified vaccinia virus strains for improved tumor targeting.

Main Methods:

  • Review of existing literature on recombinant vaccinia virus applications.
  • Analysis of vaccinia virus gene functions in cell cycle control and defense mechanisms.
  • Examination of vaccinia virus mutants with deleted genes (thymidine kinase, vaccinia growth factor).

Main Results:

  • rVVs have demonstrated potential as vaccines and gene delivery vectors.
  • Western Reserve strain vaccinia shows replication ability in tumor cells for virotherapy.
  • Vaccinia mutants with deleted thymidine kinase and vaccinia growth factor exhibit enhanced tumor targeting and replication efficiency.

Conclusions:

  • Modified vaccinia virus vectors offer promising strategies for cancer virotherapy and gene delivery.
  • Further research into viral gene functions can optimize vaccinia virus for enhanced antitumour efficacy.
  • Vaccinia virus holds significant potential for treating infectious diseases and cancer.

Related Experiment Videos